Clinical Trials

50 enrolled

Colonic Neoplasms, Rectal Neoplasms

NCT06607458 2026-03-13

DEL-LIVER

90 enrolled

Rectal Neoplasms, Colorectal Neoplasms

NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

35 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT05731726 2026-03-05

Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

50 enrolled

Rectal Neoplasms

NCT05672524 2026-03-04

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

37 enrolled

Adenocarcinoma, Rectal Neoplasms

NCT07433673 2026-02-25

GAP Cemi

20 enrolled

Rectal Neoplasms

NCT07292298 2026-02-19

Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

44 enrolled

Rectal Neoplasms

NCT07337876 2026-02-17

MARS

Rectal Neoplasms

NCT07407647 2026-02-12

Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer

GastrointestinalGynecologic

25 enrolled

Anus Neoplasms, Uterine Cervical Neoplasms, Rectal Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT04643366 2026-01-27

Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer

54 enrolled

Rectal Neoplasms

NCT07347951 2026-01-16

A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer

30 enrolled

Rectal Neoplasms

NCT07068763 2026-01-06

mRCAT-E

52 enrolled

Rectal Neoplasms

NCT07284992 2025-12-16

SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC

208 enrolled

Rectal Neoplasms

NCT06569368 2025-10-06

Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy

Rectal Neoplasms

NCT07198165 2025-09-30

SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC

104 enrolled

Rectal Neoplasms

NCT06577194 2025-09-19

A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy With IL-2 Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer

35 enrolled

Rectal Neoplasms

NCT06884670 2025-09-08

Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study

130 enrolled

Rectal Neoplasms

NCT06770270 2025-09-04

PUCRT

68 enrolled

Rectal Neoplasms

NCT05722288 2025-08-29

Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers

GastrointestinalGenitourinary

Prostatic Neoplasms, Rectal Neoplasms

NCT05576480 2025-08-28

SPARC

55 enrolled

Rectal Neoplasms

NCT05024097 2025-08-27

PANTHER

43 enrolled

Rectal Neoplasms

NCT05515796 2025-08-24

Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors

200 enrolled

Rectal Neoplasms, Stomach Neoplasms

NCT05254327 2025-08-07

Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001

118 enrolled

Rectal Neoplasms

NCT05732389 2025-08-07

RESET-R

39 enrolled

Rectal Neoplasms

NCT07108127 2025-08-06

NePHera

24 enrolled

Rectal Neoplasms

NCT07095439 2025-07-31

Efficacy and Toxicity of Total Neoadjuvant Sandwich Treatment Via Short Course Radiotherapy in the Treatment of Stage II and III Rectal Cancer Patients

38 enrolled

Rectal Neoplasms

NCT06780787 2025-06-26

FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery

26 enrolled

Rectal Neoplasms

NCT06949098 2025-05-29

Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low Rectal Cancer

Rectal Neoplasms

NCT06908031 2025-05-14

CRIT

49 enrolled

Rectal Neoplasms

NCT05965531 2025-04-29

TASLARC

65 enrolled

Rectal Neoplasms

NCT06911684 2025-04-23

Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.

88 enrolled

Rectal Neoplasms

NCT06923345 2025-04-18

Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)

80 enrolled

Rectal Neoplasms

NCT06718543 2025-04-10

TRIUNITE-03

Rectal Neoplasms

NCT06417476 2025-03-19

Short-course Radiotherapy or Long-course Chemoradiation Followed by MFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer

66 enrolled

Rectal Neoplasms

NCT06210971 2025-03-13

Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer

Rectal Neoplasms

NCT04503694 2025-03-05

REGINA

72 enrolled

Rectal Neoplasms

NCT06812728 2025-02-19

Neoadjuvant FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Patients

Rectal Neoplasms

NCT06793137 2025-01-29

Intestinal Microbiome Modulation With Antibiotics in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer

Rectal Neoplasms

NCT06204094 2025-01-07

CASINOs

37 enrolled

Rectal Neoplasms

NCT06542588 2024-12-18

Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC

29 enrolled

Rectal Neoplasms

NCT05628038 2024-10-01

TORCH-R

93 enrolled

Rectal Neoplasms

NCT03714490 2024-05-29

SUNRISE

200 enrolled

Rectal Neoplasms

NCT05228431 2024-04-22

Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer

121 enrolled

Rectal Neoplasms

NCT06266832 2024-02-20

The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma

30 enrolled

Rectal Neoplasms

NCT06254521 2024-02-12

The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer

Rectal Neoplasms

NCT05526079 2024-01-29

Watchful Waiting for Complete Responders to Therapy in Rectal Cancer

30 enrolled

Rectal Neoplasms

NCT06162650 2023-12-08

Total Neoadjuvant Therapy in Rectal Cancer

42 enrolled

Rectal Neoplasms

NCT05957016 2023-08-23

Neoadjuvant CIETAI With Concurrent Chemoradiotherapy in Local Advanced Rectal Cancer

90 enrolled

Rectal Neoplasms

NCT05939661 2023-07-11

AMBITION

45 enrolled